Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 juil. 2019 09h02 HE | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

HOUSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that President...
24 juil. 2019 16h05 HE | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Successfully Monetizes Legacy Consumer Product

HOUSTON, July 24, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it completed...
22 juil. 2019 08h05 HE | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors

HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has...
22 juil. 2019 08h00 HE | Source: Salarius Pharmaceuticals

Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma

HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius...